HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5- ((3- cyclobutyl- 2,3,4,5- tetrahydro- 1H- 3- benzazepin- 7- yl)oxy)- N- methyl- 2- pyrazinecarboxamide

an H3 receptor antagonist; structure in first source

Also Known As:

GSK 207040; GSK-207040; GSK207040

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrazines: 150
    - 5-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-2-pyrazinecarboxamide: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - 5-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-2-pyrazinecarboxamide: 2

Experts

1.	Medhurst, Andrew D: 2 articles (01/2009 - 04/2007)
2.	Wilson, David M: 2 articles (01/2009 - 04/2007)
3.	Cilia, Jackie: 1 article (01/2009)
4.	Cluderay, Jane E: 1 article (01/2009)
5.	Dawson, Lee A: 1 article (01/2009)
6.	Gartlon, Jane E: 1 article (01/2009)
7.	Jennings, Carol A: 1 article (01/2009)
8.	Jones, Declan N C: 1 article (01/2009)
9.	Lacroix, Laurent P: 1 article (01/2009)
10.	Reavill, Charlie: 1 article (01/2009)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 01/01/2009 - "GSK207040 (3.2 mg/kg) raised extracellular concentrations of dopamine, noradrenaline, and acetylcholine in the anterior cingulate cortex and c-fos expression in the core of the nucleus accumbens was increased at doses of 3.2 and 10.0 mg/kg. The behavioral and neurochemical profile of GSK207040 supports the potential of histamine H3 receptor antagonism to treat the cognitive and sensory gating deficits of schizophrenia. "
2.	Neuralgia (Stump Neuralgia) 04/15/2007 - "Novel H(3) receptor antagonists such as GSK207040 and GSK334429 may therefore have therapeutic potential not only in dementia but also in neuropathic pain."
3.	Memory Disorders (Memory Loss) 01/01/2009 - "Acute orally administered GSK207040 was investigated for its capacity to reverse a 24-h-induced deficit in novel object recognition memory, deficits in prepulse inhibition (PPI) induced by isolation rearing, and hyperlocomotor activity induced by amphetamine. "
4.	Hyperalgesia 04/15/2007 - "In addition, GSK207040 (0.1, 0.3 and 1mg/kg p.o.) and GSK334429 (3 and 10mg/kg p.o.) significantly reversed capsaicin-induced reductions in paw withdrawal threshold, suggesting for the first time that blockade of H(3) receptors may be able to reduce tactile allodynia. " 04/15/2007 - "Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats."
5.	Dementia (Dementias) 04/15/2007 - "Novel H(3) receptor antagonists such as GSK207040 and GSK334429 may therefore have therapeutic potential not only in dementia but also in neuropathic pain."

Related Drugs and Biologics

1.	Histamine H3 Antagonists
2.	Cholinergic Antagonists (Anticholinergics)
3.	Histamine H3 Receptors (Histamine H3 Receptor)
4.	Scopolamine (Hyoscine)
5.	Norepinephrine (Noradrenaline)
6.	Dopamine (Intropin)
7.	Capsaicin (Zostrix)
8.	Amphetamine (Amfetamine)
9.	Acetylcholine (Acetylcholine Chloride)
10.	1- (1- methylethyl)- 4- ((1- (6- (trifluoromethyl)- 3- pyridinyl)- 4- piperidinyl)carbonyl)hexahydro- 1H- 1,4- diazepine